BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Fcγ receptor IIb (FCGR2B; CD32B)

April 30, 2015 7:00 AM UTC

In vitro and mouse studies suggest inhibiting FCGR2B could help treat leukemias and lymphomas resistant to anti-CD20 therapy. In primary CLL cells, an anti-FCGR2B mAb decreased internalization of rituximab compared with an isotype control. In mouse models of CLL and MCL resistant to anti-CD20 mAbs, the anti-FCGR2B mAb plus rituximab decreased the number of CLL cells in the spleen and increased survival compared with either mAb alone. In mouse models of CLL, the anti-FCGR2B mAb plus obinutuzumab or alemtuzumab decreased numbers of CLL cells in the spleen and increased survival compared with any mAb alone. Next steps could include testing the anti-FCGR2B mAb and rituximab in preclinical models of non-Hodgkin's lymphoma (NHL).

Biogen Inc. and the Genentech Inc. unit of Roche market Rituxan rituximab, a chimeric mAb against CD20, to treat CLL, NHL, lymphoma, multiple sclerosis (MS), rheumatoid arthritis (RA) and inflammation...